Compare ResMed Inc. (RMD) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Thomson Reuters Corp — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while Thomson Reuters Corp trades at $90.5 (market cap $41.28B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| RMD | TRI | |
|---|---|---|
Market Cap | $28.81B | $41.28B |
Sector | Health | Industrials |
52-Week High | $293.73 | $205.54 |
52-Week Low | $182.82 | $76.55 |
Enterprise Value | $27.99B | $43.24B |
Dividend Yield | 1.21% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Thomson Reuters (TRI) trades at $90.67, down 5.75% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.93% net margin and 12.63% ROE, though recent earnings showed mixed results with a Q4 2025 miss. Recent developments include a joint venture with KKR for the global print business and strategic AI implementation, positioning TRI for future growth in content and technology services.
Wall Street remains optimistic with a $129.96 consensus price target (43% upside), driven by 51.85% buy ratings. Key risks include execution of AI strategy and competitive pressures. The stock offers value with reasonable valuation multiples (P/E 27.47, P/S 5.49) and consistent dividend payments, making it attractive for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
